Teslascan

RSS

Withdrawn

This medicine's authorisation has been withdrawn

mangafodipir
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 22 May 1997 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Teslascan (mangafodipir) for diagnostic use only. Contrast medium for diagnostic Magnetic Resonance Imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. As an adjunct to MRI to aid in the investigation of focal pancreatic lesions. The marketing authorisation holder (MAH) responsible for Teslascan was GE Healthcare AS. 

The European Commission was notified by a letter dated 4 May 2012 of the MAH’s decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for Teslascan for commercial reasons. On 21 June 2012 the European Commission issued a decision to withdraw the marketing authorisation for Teslascan. 

Pursuant to this decision the European Public Assessment Report for Teslascan is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (464.54 KB - PDF)

Amharc

español (ES) (278.32 KB - PDF)

Amharc

čeština (CS) (438.66 KB - PDF)

Amharc

dansk (DA) (277.64 KB - PDF)

Amharc

Deutsch (DE) (278.47 KB - PDF)

Amharc

eesti (ET) (277.09 KB - PDF)

Amharc

ελληνικά (EL) (530.02 KB - PDF)

Amharc

français (FR) (279.35 KB - PDF)

Amharc

italiano (IT) (277.94 KB - PDF)

Amharc

latviešu (LV) (442.86 KB - PDF)

Amharc

lietuvių (LT) (416.09 KB - PDF)

Amharc

magyar (HU) (428.93 KB - PDF)

Amharc

Malti (MT) (443.1 KB - PDF)

Amharc

Nederlands (NL) (278.24 KB - PDF)

Amharc

polski (PL) (446.02 KB - PDF)

Amharc

português (PT) (278.72 KB - PDF)

Amharc

română (RO) (410.52 KB - PDF)

Amharc

slovenčina (SK) (435.62 KB - PDF)

Amharc

slovenščina (SL) (668.03 KB - PDF)

Amharc

suomi (FI) (276.88 KB - PDF)

Amharc

svenska (SV) (277.16 KB - PDF)

Amharc

Product information

български (BG) (464.54 KB - PDF)

Amharc

español (ES) (278.32 KB - PDF)

Amharc

čeština (CS) (438.66 KB - PDF)

Amharc

dansk (DA) (277.64 KB - PDF)

Amharc

Deutsch (DE) (278.47 KB - PDF)

Amharc

eesti (ET) (277.09 KB - PDF)

Amharc

ελληνικά (EL) (530.02 KB - PDF)

Amharc

français (FR) (279.35 KB - PDF)

Amharc

italiano (IT) (277.94 KB - PDF)

Amharc

latviešu (LV) (442.86 KB - PDF)

Amharc

lietuvių (LT) (416.09 KB - PDF)

Amharc

magyar (HU) (428.93 KB - PDF)

Amharc

Malti (MT) (443.1 KB - PDF)

Amharc

Nederlands (NL) (278.24 KB - PDF)

Amharc

polski (PL) (446.02 KB - PDF)

Amharc

português (PT) (278.72 KB - PDF)

Amharc

română (RO) (410.52 KB - PDF)

Amharc

slovenčina (SK) (435.62 KB - PDF)

Amharc

slovenščina (SL) (668.03 KB - PDF)

Amharc

suomi (FI) (276.88 KB - PDF)

Amharc

svenska (SV) (277.16 KB - PDF)

Amharc
Latest procedure affecting product information:II/0016
23/10/2009
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (326.76 KB - PDF)

Amharc

español (ES) (270.54 KB - PDF)

Amharc

čeština (CS) (296.26 KB - PDF)

Amharc

dansk (DA) (274.09 KB - PDF)

Amharc

Deutsch (DE) (275.77 KB - PDF)

Amharc

eesti (ET) (266.06 KB - PDF)

Amharc

ελληνικά (EL) (304.35 KB - PDF)

Amharc

français (FR) (270.47 KB - PDF)

Amharc

italiano (IT) (269.3 KB - PDF)

Amharc

latviešu (LV) (298.43 KB - PDF)

Amharc

lietuvių (LT) (287.65 KB - PDF)

Amharc

magyar (HU) (287.43 KB - PDF)

Amharc

Malti (MT) (319.82 KB - PDF)

Amharc

Nederlands (NL) (271.56 KB - PDF)

Amharc

polski (PL) (299.17 KB - PDF)

Amharc

português (PT) (278.53 KB - PDF)

Amharc

română (RO) (308.72 KB - PDF)

Amharc

slovenčina (SK) (296.85 KB - PDF)

Amharc

slovenščina (SL) (505.18 KB - PDF)

Amharc

suomi (FI) (267.89 KB - PDF)

Amharc

svenska (SV) (273.51 KB - PDF)

Amharc

Product details

Name of medicine
Teslascan
Active substance
mangafodipir trisodium
International non-proprietary name (INN) or common name
mangafodipir
Therapeutic area (MeSH)
Magnetic Resonance Imaging
Anatomical therapeutic chemical (ATC) code
V08CA05

Pharmacotherapeutic group

Contrast media

Therapeutic indication

This medicinal product is for diagnostic use only.

Contrast medium for diagnostic magnetic resonance imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. As an adjunct to MRI to aid in the investigation of focal pancreatic lesions.

Authorisation details

EMA product number
EMEA/H/C/000137
Marketing authorisation holder
GE Healthcare AS

Nycoveien 1
NO-0401 Oslo
Norway

Marketing authorisation issued
22/05/1997
Withdrawal of marketing authorisation
21/06/2012
Revision
9

Assessment history

This page was last updated on

Share this page